

Special Issue

The Metabolic Landscape of Gynecological Cancer: Identifying Targets for Therapeutic Intervention

Message from the Guest Editor

Gynecological cancer (comprised of ovarian/fallopian tube, primary peritoneal, endometrial, cervical, vulvar, and vaginal cancers) are distinct in their origin and etiology. Nonetheless, surgery coupled with chemo/radiation therapy has long been the standard of care and has yielded little patient benefit. Therefore, there is a need to understand these diseases better and identify novel approaches to targeting gynecological cancer. While biologicals targeting angiogenesis, DNA repair and immunotherapy have shown promise in clinical studies, the metabolic targeting of gynecological cancer remains less explored. The aim of this Special Issue is to showcase original research articles, reviews, perspectives, clinical trials, and short communications highlighting metabolic features of gynecological cancer, with the objective to identify potential approaches that would lead to therapeutic interventions. This Special Issue will help generate interest and provide insights into the metabolic targeting of gynecological cancers.

Guest Editor

Dr. Abir Mukherjee

Department of Obstetrics & Gynecology, The University of Chicago, Chicago, IL, USA

Deadline for manuscript submissions

closed (28 April 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/184075

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)